m****g
发帖数: 530 | 1 I heard after their nature published, they already received several calls
from patients who are eager to try the
drug for the NSCLC. that drug is specifically targetting one of the most
popular NSCLC current drug induced
mutationT790M, and this lacks therapy in clinic right now. | m****g
发帖数: 530 | 2 this T790M mutation in EGFR does not respond to any of the current therapy.
it is a very popular area now. a lot of drug companies is rushing on this
area. looks like NSCLC is one of the big area in the oncology now. people
have tried different drug approaches to fight with this number killer in
the cancer area in US now, including the reversible kinase inhbitor( more
traditional approach), irreversible EGFR inhibitors and combination
therapies like combing EGGR inhibitors with chemotherapy |
|
